AUSTIN, Texas, May 11, 2023 /PRNewswire/ -- Anebulo Pharmaceuticals, Inc. (Nasdaq:ANEB), a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid intoxication (ACI) and substance abuse (the "Company" or "Anebulo"), today announced financial results for the three months ended March 31, 2023, and recent updates.
Read more at prnewswire.comAnebulo Pharmaceuticals Reports Third Quarter Fiscal 2023 Financial Results and Recent Updates
PR Newswire - Press Release
All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here